To answer this question, we used the TIDE algorithm and found that BLCA patients with higher LRP1 expression had higher TIDE scores and tended to have weaker responsiveness to immunotherapy treatment (p<0.001) (Figure 5F). Here, LRP1 is linked to bladder transitional cell carcinoma.